您的位置：
> 百健艾迪中国
绿色等级：
(请点击颜色评级)
人气：1789 评论：
百健艾迪在中国的官方网站。百健艾迪（Biogen Idec）公司是全球生物技术产业巨擘，是位于美国麻塞诸塞州的生物科技公司，专门从事神经系统疾病、自体免疫性疾病和癌症药物的开发。
百健艾迪医药咨询（上海）有限公司
电话：86-21-传真：86-21-电子邮箱：china.地址：上海市南京西路1266号恒隆广场1座室。
热门网站分类标签
本类网站排行
网站名称人气
访问该网站的用户还访问了:百健艾迪/Sobi血友病药物ELOCTA进入EMA实质审评阶段
【新药汇讯】 10月31日，百健艾迪与Sobi宣布欧洲药品管理局(EMA)接受ELOCTA(rFVIIIFc)的上市许可申请(MAA)，这是一款用于血友病A治疗的重组因子VIII Fc融合蛋白候选药物。
10月31日，百健艾迪与Sobi宣布欧洲药品管理局(EMA)接受ELOCTA(rFVIIIFc)的上市许可申请(MAA)，这是一款用于血友病A治疗的重组因子VIII Fc融合蛋白候选药物。这次MAA的接受使这款产品在EMA进入实质性审查程序。
ELOCTA是rFVIIIFc在欧洲的商品名，这款产品在美国、加拿大及澳大利亚还被称作ELOCTATE[抗血友病因子(重组体), Fc融合蛋白]，用于血友病A治疗。ELOCTATE是首款在血液中循环时间延长的重组凝血因子VIII治疗药物，可以为出血发作提供预防，并且两次预防性注射之间的时间间隔有可能延长。
&ELOCTA的申请得到EMA确认是朝着将这款创新型治疗药物带给欧洲血友病患者迈出的重要一步，&百健艾迪研发执行副总裁、哲学博士Williams称。&ELOCTA有可能预防出血发作，同时有助于解决频繁注射问题。&
这次的监管申请包括关键3期临床研究A-LONG与Kids A-LONG的结果，A-LONG研究在患有严重血友病A的12岁及以上年龄男性患者中测试了rFVIIIFc的有效性、安全性及药代动力学，Kids A-LONG在患有血友病的12岁以下儿童患者中评价了rFVIIIFc的有效性和安全性。
百健艾迪与Sobi在ELOCTATE/ELOCTA用于血友病A的开发及商业化中进行合作。Sobi有权选择在自己的领地（欧洲、北非、俄罗斯及大部分中东市场）接管最终的ELOCTA开发及商业化，百健艾迪主导ELOCTATE/ELOCTA的开发，拥有生产权，在北美及全球Sobi领地之外的其它区域拥有商业化权利。
&Sobi与百健艾迪致力于在全球血友病领域解决重要的医疗需求，& Sobi研发高级副总裁及首席医疗官、医学博士及哲学博士Volck称。&我们正合作开发有可能改变血友病A治疗方式的创新型药物。&
By&Heather Cunnings, on&&in&
[Business Wire] & CAMBRIDGE, Mass. & STOCKHOLM&(BUSINESSWIRE)& Biogen Idec (NASDAQ:BIIB & News) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI.ST & News) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) of ELOCTA& (rFVIIIFc), a recombinant factor VIII Fc fusion protein product candidate for the treatment of hemophilia A. The validation of the MAA initiates the EMA&s review process. ELOCTA is the European trade name for rFVIIIFc, which is also known as ELOCTATE& [Antihemophilic Factor (Recombinant), Fc Fusion Protein] in the U.S., Canada, and Australia, wher it is approved for the treatment of hemophilia A. ELOCTATE is the first recombinant clotting factor VIII therapy with prolonged circulation to provide protection from bleeding episodes with the potential for an extended interval between prophylactic injections. &The validation of ELOCTA&s application by the EMA is an important step toward bringing this innovative treatment to people with hemophilia A in Europe,& said Douglas E. Williams, Ph.D., executive vice president of Research and Development at Biogen Idec.
Biogen Idec Inc. (BIIB), with a current market cap of $75.82B, started trading this morning at $330.00.&
Today, shares have traded between $318.66 and $330.50 per share and has traded between $230.25 and $358.89 over the past 12 months.&
Biogen (BIIB)&shares are currently priced at 23.76x this year&s forecasted earnings, which makes them relatively expensive compared to the industry&s 5.60x earnings multiple for the same period.&
In a review of the consensus earnings estimate this quarter, 19 sell-side analysts are looking at $3.76 per share, which would be $1.42 better than the year-ago quarter and a $0.05 sequential increase. The full-year EPS estimate is $13.51 which would be a $4.55 better than last year&s full-year earnings.&
The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $2.64 Billion. If realized, that would be a 34.01% increase over the year-ago quarter.&
More recently,&Robert W. Baird upgraded BIIB from Neutral to Outperform (Oct 22, 2014). Previously, FBR Capital Initiated BIIB at to Mkt Perform.&
Investors should keep in mind is that the average price target is $373.00, which is 13.03% above wher the stock opened this morning.&
:&&Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVonEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn? RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); FUMADERM to treat severe plaque psorias FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company?s products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibit and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company?s Phase II clinical trial products include Anti-LINGO STX-100 for idiopathic pulmo Neublastin
and ANTI-TWAEK for lupus nephritis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer& BIIB037 for MS; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial products include ISIS-SMNRx for spinal muscular atrophy. Biogen Idec Inc. has collaboration agreements with Genentech, Inc.; Acorda Therapeutics, Inc.; Sangamo BioS and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.&
新药汇是专业新药技术服务和成果转让平台，提供新药临床批件，新药证书转让，新药外包技术服务信息！,-新药汇
市场合作 / 会员升级 / 广告投放热线：['ba??d??n]
n. 生原体；酵母促生物原
行家：灰眼圈时间：日 百健（Biogen）是世界上知名度最高的生物医药公司之一，甚至许多不熟悉生物医药产业的人可能都听说过它的大名。
基于279个网页-
生物学专业英语词汇(B)-英语词汇汇总-词汇中心-... ... biogas 生物气 biogen 生源体 biogenesis 生源说 ...
基于81个网页-
酵母促生物原
化学化工英语词汇第541页 ... bioenergetics生物能学 biogen酵母促生物原 biogeochemistry生物地球化学 ...
基于75个网页-
...、狂风使），所以一位豪杰可以是生物尖兵、电浆狂风使或是死灵复仇者，依此类推。孢子中文版下载， 基因范例 生物基因（BioGen）：可启用针刺外皮等防御能力，和剧毒气味或胶葛藤蔓等进击能力； 生化基因（CyberGen）：运用了纳米机械人带来快速医治、超快处置...
基于61个网页-
英国生物质能协会
百健艾迪公司
拜耳基因公司
美国生物科技公司百健
绿纤素牌纤维营养粉
国百健艾迪艾尔斯公司
百健艾迪公司
德国标正作物科学有限公司
更多收起网络短语
酵母促生物原
&2,447,543篇论文数据，部分数据来源于
['bai?d??n]
【生物化学】生命索，生源体
以上来源于：《21世纪大英汉词典》
/'ba??d??n/
a hypothetical protein assumed to be the basis of the formation and functioning of body cells and tissues 生原体
n. 生原体；酵母促生物原
U.S. life science companies, ranging from big pharmas such as Merck (MRK) and Pfizer (PFE) to biotechs such as Biogen-Idec (BIIB) are also eagerly collaborating with Chinese counterparts.
美国生命科学企业，从默克（Merck）和辉瑞（Pfizer）等大型制药公司到艾迪克（Biogen-Idec）等生物技术公司，都渴望与中国同行展开合作。
The result is a city that is home to a cluster of life-sciences and technology companies like Qualcomm, Biogen Idec and Gen-Probe.
最后这座城市聚集了一大群像高通、Biogen Idec和Gen – Probe等生命科学的高科技公司。
And a similar--but less extreme--calculus applies to other companies being touted as potential Biogen buyers.
That would be a huge distraction for researchers both at Pfizer and at Biogen.
The newly approved psoriasis medicine, Raptiva, will battle it out with Amgen and Biogen Idec drugs.
$firstVoiceSent
- 来自原声例句
请问您想要如何调整此模块？
感谢您的反馈，我们会尽快进行适当修改！
请问您想要如何调整此模块？
感谢您的反馈，我们会尽快进行适当修改！